Concise report Figure 2 User interface of the electronic tool. NSAID, non-steroidal anti-inﬂammatory drug; PPI, proton pump inhibitor. Given the complexity of data and to avoid the risk of oversim- pliﬁcation, we feel that an electronic tool (see ﬁgure 2) may offer the best opportunities as a quick reference guide to the panel results. In the complex and dynamic area of NSAID use, we feel that such an approach will offer the best chances of beneﬁting from the perspective of both science and practice. Funding The study was supported by an unrestricted educational grant from Pﬁzer. The sponsor was not involved in the panel process and preparation of the manuscript. Competing interests Panel members received honoraria from Pﬁzer for the rating activities and their participation in the panel meetings. GB has received fees for clinical trials from Pﬁzer and is a member of advisory boards and speakers bureau of Pﬁzer Germany and MSD Germany. AL has participated as a member of the steering committee of the CONDOR trial and as a speaker in symposiums sponsored by Pﬁzer. AL has also been advisor to AstraZeneca. LB has received fees for speeches and consultancy from Pﬁzer, Siemens diagnostic, Sanoﬁ-Aventis and Merck. LB has also received a grant from Sanoﬁ-Aventis. MH has received speaking fees from Pﬁzer and Novartis. SL has received honoraria as a member of advisory boards to Abbott, Boehringer, MerckSerono, NicOx, Pﬁzer, Sanoﬁ-Aventis. IO received consulting fees, speaking fees and/or honoraria from Schering-Plough, Bristol-Myers Squibb, Pﬁzer-Wyett, Abbott, Merck Pharmaceutical, Novartis, Sanoﬁ-Aventis and Roche. CS is on the speakers bureau of Pﬁzer, AstraZeneca and SIDEM Pharma. His laboratory has received research grants from Pﬁzer. JS has received honoraria for advisory board activities from Pﬁzer and Novartis. HS has received honoraria from Pﬁzer for advice to the design of the study and data analysis. TMM has received research grants from Novartis, Pﬁzer, Ipsen & Menarini; principal investigator for Pﬁzer, Novartis, Ipsen & Menarini; received consulting or speakers fees from Pﬁzer, Novartis, Kaiser Permanente, Takeda, Recordati, Servier, Menarini, NiCox & AstraZeneca. CJH received research funding and/or honoraria from AstraZeneca, Atlantic Pharmaceuticals, Bayer, Logical Therapeutics, Novartis Pharma, Pﬁzer and Reckitt Benckiser. FB received speaker honoraria from Abbott Laboratories. TM, PD, FB, EMM, AB, MD, NVDN: none apart from the general statement in the article: “Panel members received honoraria from Pﬁzer for the rating activities and their participation in the panel meetings.” Provenance and peer review Not commissioned; externally peer reviewed. Authors afﬁliations 1Department of Rheumatology and Clinical Immunology, Charité – University Medicine, Free University and Humboldt University Berlin, Berlin, Germany 2Department of Gastroenterology, University of Zaragoza, Zaragoza, Spain 3Institute of Cardiovascular, Medicine, Catholic University, Rome, Italy 4Department of Cardiology, University Hospital Zürich, Zürich, Switzerland Ann Rheum Dis 2011;70:818–822. doi:10.1136/ard.2010.128660 5Department of Clinical, Sciences, Lund University, Lund, Sweden 6Department of Rheumatology, Ospedale San Carlo, Potenza, Italy 7Department of Clinical Sciences, Division of Gastroenterology, University of Parma, Parma, Italy 8Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria 9Nottingham Digestive Diseases Centre & BRU, University Hospital, Nottingham, UK 10Bradshaw Medical Centre and Steering Committee representative of the Primary Care Rheumatology Society, Orrell, Wigan, UK 11Department of Rheumatology, University Pierre & Marie Curie Paris VI, Saint-Antoine hospital, AP-HP, Paris, France 12Leiden University Medical Centre, Leiden, The Netherlands 13Department of General Medicine, University of Antwerp (ELIZA), Wilrijk, Belgium 14Paris-Descartes University, Medicine Faculty; UPRES EA 4058; AP-HP, Cochin Hospital, Rheumatology B Dept, Paris, France 15Medicines Monitoring Unit (MEMO), Division of Medical Sciences, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK 16Department of Rheumatology, Hospital Universitario La Paz, Autonoma University Madrid, Madrid, Spain 17Department of Gerontology & Geriatrics VUB, University Hospital, Brussels, Belgium 18Department of Geriatric Medicine, University Hospital Ghent, Ghent, Belgium 19Centre for Decision Analysis and Support, Ismar Healthcare, Lier, Belgium REFERENCES 1. Hur C, Chan AT, Tramontano AC, et al. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, beneﬁts, and costs. Ann Pharmacother 2006;40:1052–63. 2. Garner SE, Fidan DD, Frankish RR, et al. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2002;4:CD003831. 3. Deeks JJ, Smith LA, Bradley MD. Efﬁcacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619–23. 4. Richy F, Scarpignato C, Lanas A, et al. Efﬁcacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials. Pharmacol Res 2009;60:254–63. 5. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inﬂammatory drugs—nice or necessary? Rev Gastroenterol Disord 2004;4(Suppl 4):S33–41. 6. Schoenfeld P, Kimmey MB, Scheiman J, et al. Review article: nonsteroidal anti-inﬂammatory drug-associated gastrointestinal complications – guidelines for prevention and treatment. Aliment Pharmacol Ther 1999;13:1273–85. 7. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inﬂammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 2000;7:115–21. 821